PTCT Stock Analysis: PTC Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.003m USD | 12M Return: 69.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 162M
Qual. Beats: 0
Rev. Trend: 59.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PTC Therapeutics, Inc. is a U.S.-based biopharmaceutical company headquartered in Warren, New Jersey, that discovers, develops, and commercializes treatments for rare disorders globally. Its marketed portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (marketed as Kebilidi in the U.S.) for AADC deficiency, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy.
The companys development pipeline targets additional rare conditions, including Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease, and vatiquinone for Friedreichs ataxia, supported by platforms in splicing, inflammation, and ferroptosis. As a rare disease specialist, PTC relies on third-party distributors for product delivery and maintains strategic collaborations and licensing agreements with major partners such as Roche, Novartis, the SMA Foundation, and Akcea Therapeutics.
- DMD franchise Translarna and Emflaza sales face regulatory headwinds
- Evrysdi SMA royalties from Roche expand as prescriptions grow
- PTC518 Huntingtons program milestone payments from Novartis advance
| Net Income: -186.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -28.90 > 1.0 |
| NWC/Revenue: 160.8% < 20% (prev 97.08%; Δ 63.77% < -1%) |
| CFO/TA -0.08 > 3% & CFO -217.9m > Net Income -186.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.5m) vs 12m ago -4.47% < -2% |
| Gross Margin: 77.84% > 18% (prev 96.87%; Δ -19.03% > 0.5%) |
| Asset Turnover: 29.94% > 50% (prev 66.76%; Δ -36.82% > 0%) |
| Interest Coverage Ratio: -2.41 > 6 (EBIT TTM -166.6m / Interest Expense TTM 69.1m) |
| A: 0.46 (Total Current Assets 2.25b - Total Current Liabilities 923.6m) / Total Assets 2.87b |
| B: -1.03 (Retained Earnings -2.97b / Total Assets 2.87b) |
| C: -0.06 (EBIT TTM -166.6m / Avg Total Assets 2.76b) |
| D: -0.06 (Book Value of Equity -180.5m / Total Liabilities 3.05b) |
| Altman-Z'' = -0.80 = CCC |
| DSRI: 2.24 (Receivables 219.9m/210.5m, Revenue 827.1m/1.77b) |
| GMI: 1.24 (GM 96.87% / 77.84%) |
| AQI: 2.02 (AQ_t 0.17 / AQ_t-1 0.08) |
| SGI: 0.47 (Revenue 827.1m / 1.77b) |
| TATA: 0.01 (NI -186.7m - CFO -217.9m) / TA 2.87b) |
| Beneish M = -1.56 (Cap -4..+1) = CCC |
As of July 03, 2026, the stock is trading at USD 83.31 with a total of 1,667,787 shares traded. Over the past week, the price has changed by -1.42%, over one month by +22.10%, over three months by +22.93% and over the past year by +69.50%.
Current recommended Stop Loss: 76.80 (which is 7.8% or 2.1 ATR below the current price).
PTC Therapeutics has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PTCT.
- StrongBuy: 5
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 93.9 | 12.7% |
P/E Forward = 60.9756
P/S = 8.4673
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 827.1m USD
EBIT TTM = -166.6m USD
EBITDA TTM = -119.6m USD
Long Term Debt = 2.03b USD (from longTermDebt, last fiscal year)
Short Term Debt = 305.0m USD (from shortTermDebt, last quarter)
Debt = 2.44b USD (corrected: LT Debt 2.03b + ST Debt 305.0m) + Leases 108.2m
Net Debt = 2.22b USD (calculated: Debt 2.44b - CCE 214.6m)
Enterprise Value = 9.23b USD (7.00b + Debt 2.44b - CCE 214.6m)
Interest Coverage Ratio = -2.41 (Ebit TTM -166.6m / Interest Expense TTM 69.1m)
EV/FCF = -87.14x (Enterprise Value 9.23b / FCF TTM -105.9m)
FCF Yield = -1.15% (FCF TTM -105.9m / Enterprise Value 9.23b)
FCF Margin = -12.80% (FCF TTM -105.9m / Revenue TTM 827.1m)
Net Margin = -22.58% (Net Income TTM -186.7m / Revenue TTM 827.1m)
Gross Margin = 77.84% ((Revenue TTM 827.1m - Cost of Revenue TTM 183.3m) / Revenue TTM)
Gross Margin QoQ = 85.47% (prev 90.10%)
Tobins Q-Ratio = 3.22 (Enterprise Value 9.23b / Total Assets 2.87b)
Interest Expense / Debt = 2.83% (Interest Expense 69.1m / Debt 2.44b)
Taxrate = 2.01% (14.0m / 696.6m)
NOPAT = -163.2m (EBIT -166.6m * (1 - 2.01%)) [loss with tax shield]
Current Ratio = 2.37 (Total Current Assets 2.25b / Total Current Liabilities 949.1m)
Debt / Equity = -13.51 (negative equity) (Debt 2.44b / totalStockholderEquity, last quarter -180.5m)
Debt / EBITDA = -18.60 (negative EBITDA) (Net Debt 2.22b / EBITDA -119.6m)
Debt / FCF = -21.00 (negative FCF - burning cash) (Net Debt 2.22b / FCF TTM -105.9m)
Total Stockholder Equity = -187.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.76% (Net Income -186.7m / Total Assets 2.87b)
RoE = 99.84% (negative equity) (Net Income TTM -186.7m / Total Stockholder Equity -187.0m)
RoCE = -9.06% (EBIT -166.6m / Capital Employed (Equity -187.0m + L.T.Debt 2.03b))
RoIC = -7.39% (negative operating profit) (NOPAT -163.2m / Invested Capital 2.21b)
WACC = 6.75% (E(7.00b)/V(9.44b) * Re(8.14%) + D(2.44b)/V(9.44b) * Rd(2.83%) * (1-Tc(0.02)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 4.02%
[DCF] Fair Price = unknown (Cash Flow -105.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.12 | # QB: 0
Revenue Correlation: 59.23 | Revenue CAGR: 26.31% | SUE: 0.16 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.47 | Chg30d=+191.02% | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=1.31 | Chg30d=+166.66% | Revisions=+20% | GrowthEPS=-82.8% | GrowthRev=-32.2%
EPS next Year (2027-12-31): EPS=2.78 | Chg30d=+14.54% | Revisions=+20% | GrowthEPS=+111.9% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: +20%